4:59 PM
 | 
Jan 10, 2013
 |  BC Extra  |  Top Story

FDA panel backs J&J's canagliflozin

FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 10-5 to recommend approval of diabetes product Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ). Four of the panel members who voted...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >